CTLA4 and myocarditis: The complementarity of different mechanisms leads to a higher frequency of myocarditis, which is consistent with the higher clinical incidence of myocarditis induced by anti-PD-1/PD-L1 therapy coupled with anti-CTLA-4 therapy.